{"id":20974,"date":"2022-03-24T11:56:28","date_gmt":"2022-03-24T10:56:28","guid":{"rendered":"https:\/\/idibell.cat\/?p=20974"},"modified":"2022-03-24T11:56:28","modified_gmt":"2022-03-24T10:56:28","slug":"un-assaig-clinic-internacional-mostra-els-beneficis-dun-farmac-en-pacients-hospitalitzats-per-insuficiencia-cardiaca-aguda","status":"publish","type":"post","link":"https:\/\/idibell.cat\/2022\/03\/un-assaig-clinic-internacional-mostra-els-beneficis-dun-farmac-en-pacients-hospitalitzats-per-insuficiencia-cardiaca-aguda\/","title":{"rendered":"Un assaig cl\u00ednic internacional mostra els beneficis d\u2019un f\u00e0rmac en pacients hospitalitzats per insufici\u00e8ncia card\u00edaca aguda"},"content":{"rendered":"<p>Segons els resultats de l\u2019assaig cl\u00ednic fase III EMPULSE, els pacients ingressats per insufici\u00e8ncia card\u00edaca aguda tenen un <strong>36% m\u00e9s de possibilitats d\u2019experimentar millores en un termini de 90 dies en rebre tractament amb empagliflozina<\/strong>, un f\u00e0rmac ja existent que\u00a0 es prescriu sobretot per a la diabetis tipus 2. El Dr. Josep Comin, cap del grup de recerca en Malalties cardiovasculars i cap del Servei de Cardiologia de l\u2019Hospital de Bellvitge, ha estat el coordinador estatal de l\u2019assaig, en que han participat professionals i centres de 17 pa\u00efsos de tot el m\u00f3n.<\/p>\n<p>A l\u2019estudi, publicat per la revista <a href=\"https:\/\/doi.org\/10.1038\/s41591-021-01659-1\"><em>Nature Medicine<\/em><\/a>, han participat <strong>530 pacients hospitalitzats<\/strong> i estabilitzats despr\u00e9s de patir una insufici\u00e8ncia card\u00edaca aguda. Per avaluar la millora en rebre el tractament amb empaglifozina s\u2019ha utilitzat un criteri de valoraci\u00f3 combinat de mortalitat, hospitalitzacions i qualitat de vida durant 90 dies, comparat entre un grup que va rebre el f\u00e0rmac i un altre al qual es va administrar un placebo.<\/p>\n<p>Segons destaca el <strong>Dr. Josep Comin<\/strong>, \u201c<em>l\u2019hospitalitzaci\u00f3 \u00e9s un moment molt fr\u00e0gil per al pacient amb una insufi\u00e8ncia card\u00edaca aguda i alhora podem obtenir el m\u00e0xim rendiment en la prevenci\u00f3 de nous esdeveniments adversos. En aquest sentit, els resultats de l\u2019estudi poden canviar la pr\u00e0ctica cl\u00ednica amb aquests pacients<\/em>\u201d.<\/p>\n<p>L\u2019empagliflozina \u00e9s un inhibidor altament selectiu del contransportadors 2 de glucosa i sodi (SGLT2). En pacients amb diabetes tipus 2, aquest inhibidor impedeix l\u2019absorci\u00f3 de glucosa en sang al rony\u00f3, reduint-se els nivells de glucosa en sang. A m\u00e9s de la seva utilitzaci\u00f3 per a la diabetis 2, l\u2019empagliflozina tamb\u00e9 esta aprovada a Europa i Estats Units per al tractament de la IC cr\u00f2nica amb fracci\u00f3 d\u2019ejecci\u00f3 redu\u00efda (el cor no aconsegueix bombejar prou sang amb cada contracci\u00f3). Fins ara, per\u00f2, no s\u2019havien avaluat els seus beneficis durant l\u2019hospitalitzaci\u00f3 d\u2019una insufici\u00e8ncia card\u00edaca aguda.<\/p>\n<p>Segons dades de la Societat Espanyola de Cardiologia, a l\u2019Estat es registren m\u00e9s de <strong>107.000 ingressos hospitalaris anuals provocats per insufici\u00e8ncia card\u00edaca<\/strong>, i \u00e9s la primera causa d\u2019hospitalitzaci\u00f3 en les persones de m\u00e9s de 65 anys.<\/p>\n<p>A <strong>l\u2019assaig cl\u00ednic EMPULSE, fase tres i multic\u00e8ntric<\/strong>, han participat professionals i centres de Pa\u00efsos Baixos, Alemanya, Estats Units, Austr\u00e0lia, Pol\u00f2nia, Portugal, Singapur, Xina, Dinamarca, Su\u00e8cia, B\u00e8lgica, Hongria, Jap\u00f3, Rep\u00fablica Txeca, It\u00e0lia, Canad\u00e0 i Espanya. L\u2019estudi forma part del programa EMPOWER que impulsen de forma conjunta els laboratoris Boehringer Ingelheim i Eli Lilly and Company.<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p><em>L\u2019Institut d\u2019Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL) \u00e9s un centre de recerca en biomedicina creat l\u2019any 2004. Est\u00e0 participat per l\u2019Hospital Universitari de Bellvitge i l\u2019Hospital de Viladecans de l\u2019Institut Catal\u00e0 de la Salut, l\u2019Institut Catal\u00e0 d\u2019Oncologia, la Universitat de Barcelona i l\u2019Ajuntament de l\u2019Hospitalet de Llobregat.<\/em><\/p>\n<p><em>L\u2019IDIBELL \u00e9s membre del Campus d\u2019Excel\u00b7l\u00e8ncia Internacional de la Universitat de Barcelona HUBc i forma part de la instituci\u00f3 CERCA de la Generalitat de Catalunya. L\u2019any 2009 es va convertir en un dels cinc primers centres d\u2019investigaci\u00f3 espanyols acreditats com a institut d\u2019investigaci\u00f3 sanit\u00e0ria per l\u2019Instituto de Salud Carlos III. A m\u00e9s, forma part del programa \u201cHR Excellence in Research\u201d de la Uni\u00f3 Europea i \u00e9s membre de EATRIS i REGIC. Des de l\u2019any 2018, l\u2019IDIBELL \u00e9s un Centro Acreditado de la Fundaci\u00f3n Cient\u00edfica AECC (FCAECC).<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Segons els resultats de l\u2019assaig cl\u00ednic fase III EMPULSE, els pacients ingressats per insufici\u00e8ncia card\u00edaca aguda tenen un 36% m\u00e9s de possibilitats d\u2019experimentar millores en un termini de 90 dies en rebre tractament amb empagliflozina, un f\u00e0rmac ja existent que\u00a0 es prescriu sobretot per a la diabetis tipus 2. El Dr. Josep Comin, cap del [&hellip;]<\/p>\n","protected":false},"author":8,"featured_media":20981,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"default","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[359,334,466],"tags":[],"class_list":["post-20974","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-malalties-cardiovasculars","category-medicina-translacional","category-p-de-malalties-cardiovasculars-respiratories-sistemiques-i-denvelliment-cellular"],"publishpress_future_action":{"enabled":false,"date":"2024-12-28 21:46:51","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/20974","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/comments?post=20974"}],"version-history":[{"count":1,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/20974\/revisions"}],"predecessor-version":[{"id":20975,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/20974\/revisions\/20975"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media\/20981"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media?parent=20974"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/categories?post=20974"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/tags?post=20974"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}